Clinical Trials Browser

Phase 2 × Neoplasm, Residual × Docetaxel × Clear all

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT00551577 2007-10-31

PRIMOVAR-1

Phase 2 Unknown

Ovarian Neoplasms, Neoplasm, Residual